Last reviewed · How we verify
AER 001
AER 001 is an investigational monoclonal antibody targeting IL-13.
AER 001 is an investigational monoclonal antibody targeting IL-13. Used for Severe asthma.
At a glance
| Generic name | AER 001 |
|---|---|
| Also known as | AEROVANT, BAY 16-9996, Pitrakinra, AEROVANT |
| Sponsor | Aerovance, Inc. |
| Drug class | IL-13 inhibitor |
| Target | IL-13 |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
IL-13 is a cytokine involved in the pathogenesis of asthma and other allergic diseases. By targeting IL-13, AER 001 aims to reduce inflammation and improve symptoms in patients with severe asthma.
Approved indications
- Severe asthma
Common side effects
- Injection site reactions
Key clinical trials
- A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL (PHASE2)
- A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects (PHASE1)
- A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema (PHASE2)
- A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study) (PHASE2)
- Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AER 001 CI brief — competitive landscape report
- AER 001 updates RSS · CI watch RSS
- Aerovance, Inc. portfolio CI